erlotinib hydrochloride has been researched along with Invasiveness, Neoplasm in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (22.64) | 29.6817 |
| 2010's | 39 (73.58) | 24.3611 |
| 2020's | 2 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Elmquist, WF; Manchanda, P; Ohlfest, JR; Vogelbaum, MA | 1 |
| Bach, DH; Hu, R; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
| Bian, H; Birnbaumer, L; Dai, B; Feng, J; Guo, H; Hossain, MA; Hu, W; Li, L; Liu, G; Ni, J; Shen, Y; Shi, Y; Tian, Z; Wang, D; Wu, M; Yang, H; Yang, Y; Yu, D; Yu, J; Zhang, Q; Zheng, S | 1 |
| Abraham, E; Albright, C; Alistar, AT; Bitting, RL; Blackstock, W; Chen, K; D'Agostino, RB; Desnoyers, RJ; DeYoung, B; Foley, KL; Goodman, M; Grant, SC; Kytola, V; Levine, EA; Nykter, M; Pagni, M; Pasche, B; Petro, RM; Petty, WJ; Porosnicu, M; Powell, BL; Qasem, SA; Robinson, M; Staren, ED; Thomas, A; Topaloglu, U; Vatca, M; Yang, M; Zhang, W | 1 |
| Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Taketo, MM | 1 |
| Ding, X; Dong, Y; Gu, W; Song, X; Wang, Z; Wu, Y; Zhang, W; Zheng, Y; Zhong, Y | 1 |
| Liu, H; Wang, J; Wang, X; Wei, N; Zhang, F; Zhang, X | 1 |
| Li, W; Zhou, Y | 1 |
| Singh, RP; Tabasum, S | 1 |
| Chen, JE; Harley, BAC; Laken, SE; Pedron, S; Sarkaria, JN; Wolter, GL | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Dong, Z; Kang, Y; Liu, G; Ma, X; Qian, Q; Zhang, X | 1 |
| Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W | 1 |
| Basu, D; Bewley, AF; Diehl, JA; Facompre, ND; Gimotty, PA; Herlyn, M; Montone, KT; Nakagawa, H; Rasanen, K; Rustgi, AK; Sperry, SM; Weinstein, GS | 1 |
| Deitz, S; Gore, J; Korc, M; Ouyang, H | 1 |
| Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E | 1 |
| Chen, YM; Chiu, CH; Lai, SL; Lee, YC; Shih, JF; Wu, CH; Wu, WS | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Buchholz, T; Debeb, BG; Gong, Y; Klopp, A; Krishnamurthy, S; Lacerda, L; Larson, R; Levy, LB; Smith, D; Solley, T; Ueno, NT; Woodward, WA; Xu, W | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Adler-Reichel, S; Huber, RM; Rogowski, WH; Schremser, K; Stollenwerk, B; Tufman, AL | 1 |
| Ascierto, ML; Berens, ME; Briggs, M; Johnson, J; Kang, L; Marincola, FM; Mittal, S; Newsome, D; Tanner, K; Vande Woude, GF; Xie, Q | 1 |
| Cao, W; Chen, Y; Ji, T; Lin, C; Lu, W; Ren, Z; Tang, Y; Wang, L; Wang, X; Yang, R; Zhang, C | 1 |
| Feng, R; Yang, S | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Chen, XW; Han, JH; Hong, D; Ma, TC; Niu, M; Sun, J; Xu, K | 1 |
| Chen, L; Gonzalez, FJ; Gu, J; Hu, CL; Hu, L; Li, L; Li, S; Lin, XM; Liu, JF; Tang, J; Wang, HY; Wang, RY; Wu, MC; Yan, XZ; Zhang, BH; Zhou, WP; Zhu, YJ | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Calvo, E; Chen, H; Dancey, JE; Lin, CC; Mays, T; Mita, AC; Mita, MM; O'Rourke, P; Papadopoulos, KP; Patnaik, A; Preston, GG; Rodon, J; Sarantopoulos, J; Takimoto, CH; Tolcher, AW; Yeh, IT | 1 |
| Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L | 1 |
| Heinemann, V | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Fielding, J; Godley, P; Grigson, G; Heathcote, S; Kim, W; Nielsen, M; Pruthi, RS; Rathmell, WK; Schultz, H; Smith, A; Wallen, EM; Whang, Y | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Fujimoto-Ohuchi, K; Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Yanagisawa, M; Yorozu, K | 1 |
| Belousov, R; Colombo, C; Ghadimi, MP; Hornick, JL; Lazar, AJ; Lev, D; Liu, J; Lopez, G; Peng, T; Reynoso, D; Xie, X; Young, ED; Zhu, QS | 1 |
| Belani, C; Boinpally, R; Evans, J; Franke, A; Gail Eckhardt, S; Haluska, P; Leong, S; O'Bryant, CL; Ramalingam, S; Ramanathan, RK; Rosen, L; Venugopal, B; Witt, K | 1 |
| Chen, CH; Hsu, WM; Hu, RH; Huang, HC; Huang, J; Huang, MC; Huang, MJ; Lai, HS; Lee, JJ; Lee, PH; Liu, CH; Wu, YM | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Chen, ZG; Fan, S; Khuri, FR; Koo, J; Li, Y; Owonikoko, TK; Ramalingam, SS; Sun, SY; Yue, P | 1 |
| Asrani, K; Bremner, R; Cheng, E; Hostetter, G; Inge, L; Jameson, NM; Kingsley, CB; Loftus, JC; Tran, NL; Weiss, GJ; Whitsett, TG; Winkles, JA | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J | 1 |
| Greten, TF | 1 |
| Dutta, PR; Maity, A | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Bhola, NE; Grandis, JR; Gubish, CT; Lui, VW; Mills, GB; Shin, D; Siegfried, JM; Siwak, DR; Thomas, SM; Zhang, Q | 1 |
8 review(s) available for erlotinib hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
11 trial(s) available for erlotinib hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Up-Regulation | 2013 |
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasms; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Topics: Aged; Antineoplastic Agents; Cystectomy; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Protein Binding; Quinazolines | 2012 |
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
34 other study(ies) available for erlotinib hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Glioma; Neoplasm Invasiveness; Rats; Transplantation, Heterologous | 2013 |
Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Mutation; Neoplasm Invasiveness; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2020 |
PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Invasiveness; RNA-Binding Proteins; RNA-Seq; Signal Transduction; Transcription Factors; Tumor Hypoxia; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Clone Cells; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genes, erbB-1; Genes, Neoplasm; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Protein Kinase Inhibitors; Retrospective Studies; Sequence Analysis, DNA; Smoking | 2017 |
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; MAP Kinase Signaling System; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2017 |
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2018 |
CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.
Topics: beta Catenin; Carcinoma, Non-Small-Cell Lung; CD146 Antigen; Cell Movement; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Protein Kinase Inhibitors; Signal Transduction; Up-Regulation | 2019 |
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; MAP Kinase Signaling System; Melanoma; Membrane Glycoproteins; Neoplasm Invasiveness; Neovascularization, Pathologic; Up-Regulation | 2019 |
Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition.
Topics: AC133 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Flavonoids; Flavonols; Humans; Hyaluronan Receptors; Lung Neoplasms; Neoplasm Invasiveness; Phenotype; Stem Cells | 2019 |
Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gelatin; Glioblastoma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogels; Mice; Neoplasm Invasiveness; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; STAT3 Transcription Factor; Treatment Outcome; Tumor Microenvironment; Up-Regulation | 2019 |
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.
Topics: Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Lineage; Cetuximab; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; Neoplasm Invasiveness; Quinazolines; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Transforming Growth Factor beta | 2014 |
Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Sex Factors; Survival Analysis; Treatment Outcome | 2016 |
Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Culture Media, Conditioned; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Inflammatory Breast Neoplasms; Mesenchymal Stem Cells; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Signal Transduction; Stromal Cells; Tumor Burden | 2015 |
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cost-Benefit Analysis; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Germany; Humans; Lung Neoplasms; Models, Economic; Mutation; Neoplasm Invasiveness; Precision Medicine; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2015 |
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Topics: Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Hepatocyte Growth Factor; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Erlotinib Hydrochloride; Focal Adhesion Protein-Tyrosine Kinases; Humans; Neoplasm Invasiveness; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Choline Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hep G2 Cells; Humans; Immunoblotting; Immunohistochemistry; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases; Wound Healing; Xenograft Model Antitumor Assays | 2017 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation | 2008 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Neoplasm Invasiveness; Osteoblasts; Osteolysis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Quinazolines; Sarcoma; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glycosylation; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mucins; N-Acetylgalactosaminyltransferases; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polypeptide N-acetylgalactosaminyltransferase; Quinazolines; RNA, Messenger | 2011 |
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Transfection | 2012 |
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptors, Tumor Necrosis Factor; Signal Transduction; Tumor Cells, Cultured; TWEAK Receptor | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
[Molecular therapy for HCC?].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Clinical Trials as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay | 2007 |